Profile of blonanserin for the treatment of schizophrenia

Tomomi Tenjin, Seiya Miyamoto, Yuriko Ninomiya, Rei Kitajima, Shin Ogino, Nobumi Miyake, Noboru YamaguchiDepartment of Neuropsychiatry, St Marianna University School of Medicine, Kawasaki, Kanagawa, JapanAbstract: Blonanserin was developed as an antipsychotic drug in Japan and approved for the treat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tenjin T, Miyamoto S, Ninomiya Y, Kitajima R, Ogino S, Miyake N, Yamaguchi N
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/e302a7e69eba4fb2b7c5fc3a1d82f6ed
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e302a7e69eba4fb2b7c5fc3a1d82f6ed
record_format	dspace
spelling	oai:doaj.org-article:e302a7e69eba4fb2b7c5fc3a1d82f6ed2021-12-02T01:17:32ZProfile of blonanserin for the treatment of schizophrenia1176-63281178-2021https://doaj.org/article/e302a7e69eba4fb2b7c5fc3a1d82f6ed2013-04-01T00:00:00Zhttp://www.dovepress.com/profile-of-blonanserin-for-the-treatment-of-schizophrenia-a12902https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Tomomi Tenjin, Seiya Miyamoto, Yuriko Ninomiya, Rei Kitajima, Shin Ogino, Nobumi Miyake, Noboru YamaguchiDepartment of Neuropsychiatry, St Marianna University School of Medicine, Kawasaki, Kanagawa, JapanAbstract: Blonanserin was developed as an antipsychotic drug in Japan and approved for the treatment of schizophrenia. It belongs to a series of 4-phenyl-2-(1-piperazinyl)pyridines and acts as an antagonist at dopamine D2, D3, and serotonin 5-HT2A receptors. Blonanserin has low affinity for 5-HT2C, adrenergic α1, histamine H1, and muscarinic M1 receptors, but displays relatively high affinity for 5-HT6 receptors. In several short-term double-blind clinical trials, blonanserin had equal efficacy as haloperidol and risperidone for positive symptoms in patients with chronic schizophrenia and was also superior to haloperidol for improving negative symptoms. Blonanserin is generally well tolerated and has a low propensity to cause metabolic side effects and prolactin elevation. We recently reported that blonanserin can improve some types of cognitive function associated with prefrontal cortical function in patients with first-episode and chronic schizophrenia. Taken together, these results suggest that blonanserin may be a promising candidate for a first-line antipsychotic for acute and maintenance therapy for schizophrenia. Further comparative studies are warranted to clarify the benefit/risk profile of blonanserin and its role in the treatment of schizophrenia.Keywords: blonanserin, schizophrenia, pharmacology, pharmacokinetics, efficacy, safetyTenjin TMiyamoto SNinomiya YKitajima ROgino SMiyake NYamaguchi NDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2013, Iss default, Pp 587-594 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Tenjin T Miyamoto S Ninomiya Y Kitajima R Ogino S Miyake N Yamaguchi N Profile of blonanserin for the treatment of schizophrenia
description	Tomomi Tenjin, Seiya Miyamoto, Yuriko Ninomiya, Rei Kitajima, Shin Ogino, Nobumi Miyake, Noboru YamaguchiDepartment of Neuropsychiatry, St Marianna University School of Medicine, Kawasaki, Kanagawa, JapanAbstract: Blonanserin was developed as an antipsychotic drug in Japan and approved for the treatment of schizophrenia. It belongs to a series of 4-phenyl-2-(1-piperazinyl)pyridines and acts as an antagonist at dopamine D2, D3, and serotonin 5-HT2A receptors. Blonanserin has low affinity for 5-HT2C, adrenergic α1, histamine H1, and muscarinic M1 receptors, but displays relatively high affinity for 5-HT6 receptors. In several short-term double-blind clinical trials, blonanserin had equal efficacy as haloperidol and risperidone for positive symptoms in patients with chronic schizophrenia and was also superior to haloperidol for improving negative symptoms. Blonanserin is generally well tolerated and has a low propensity to cause metabolic side effects and prolactin elevation. We recently reported that blonanserin can improve some types of cognitive function associated with prefrontal cortical function in patients with first-episode and chronic schizophrenia. Taken together, these results suggest that blonanserin may be a promising candidate for a first-line antipsychotic for acute and maintenance therapy for schizophrenia. Further comparative studies are warranted to clarify the benefit/risk profile of blonanserin and its role in the treatment of schizophrenia.Keywords: blonanserin, schizophrenia, pharmacology, pharmacokinetics, efficacy, safety
format	article
author	Tenjin T Miyamoto S Ninomiya Y Kitajima R Ogino S Miyake N Yamaguchi N
author_facet	Tenjin T Miyamoto S Ninomiya Y Kitajima R Ogino S Miyake N Yamaguchi N
author_sort	Tenjin T
title	Profile of blonanserin for the treatment of schizophrenia
title_short	Profile of blonanserin for the treatment of schizophrenia
title_full	Profile of blonanserin for the treatment of schizophrenia
title_fullStr	Profile of blonanserin for the treatment of schizophrenia
title_full_unstemmed	Profile of blonanserin for the treatment of schizophrenia
title_sort	profile of blonanserin for the treatment of schizophrenia
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/e302a7e69eba4fb2b7c5fc3a1d82f6ed
work_keys_str_mv	AT tenjint profileofblonanserinforthetreatmentofschizophrenia AT miyamotos profileofblonanserinforthetreatmentofschizophrenia AT ninomiyay profileofblonanserinforthetreatmentofschizophrenia AT kitajimar profileofblonanserinforthetreatmentofschizophrenia AT oginos profileofblonanserinforthetreatmentofschizophrenia AT miyaken profileofblonanserinforthetreatmentofschizophrenia AT yamaguchin profileofblonanserinforthetreatmentofschizophrenia
_version_	1718403169392787456

Profile of blonanserin for the treatment of schizophrenia

Ejemplares similares